Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis by Mega Jessica L, Simon Tabassome, Collet Jean-Philippe, Anderson Jeffrey L, Antman Elliott M, Bliden Kevin, Cannon Christopher P, Danchin Nicolas, Giusti Betti, Gurbel Paul, Horne Benjamin D, Hulot Jean-Sebastian, Kastrati Adnan, Montalescot Gilles, Neumann Franz-Josef, Shen Lei, Sibbing Dirk, Steg P Gabriel, Trenk Dietmar, Wiviott Stephen D, Sabatine Marc S in JAMA : the journal of the American Medical Association (2010). PubMed

Abstract

Clopidogrel, one of the most commonly prescribed medications, is a prodrug requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.